[{"indications": "Indications\u00a0adjunct to co-beneldopa or co-careldopa in Parkinson\u2019s disease with\r\n\u2018end-of-dose\u2019 motor fluctuations", "name": "ENTACAPONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.9 Drugs used in parkinsonism and related disorders", "4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease", "Catechol-O-methyltransferase inhibitors", "ENTACAPONE"], "cautions": "Cautions\u00a0ischaemic heart disease; avoid abrupt withdrawal; concurrent levodopa dose may need to be reduced\r\nby about 10\u201330%; interactions: Appendix\r\n1 (entacapone)", "side-effects": "Side-effects\u00a0nausea, vomiting, abdominal pain, constipation,\r\ndiarrhoea, urine may be coloured reddish-brown, dry mouth; ischaemic\r\nheart disease; confusion, dizziness, abnormal dreams, fatigue, insomnia,\r\ndystonia, dyskinesia, hallucinations; sweating; less commonly myocardial infarction; rarely rash; very\r\nrarely anorexia, weight loss, agitation, and urticaria; also reported hepatitis, colitis, neuroleptic malignant\r\nsyndrome, rhabdomyolysis, and skin, hair, and nail discoloration", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/73634.htm", "doses": ["200\u00a0mg with each dose of levodopa with\r\ndopa-decarboxylase inhibitor; max. 2\u00a0g daily"], "pregnancy": "Pregnancy\u00a0avoid\u2014no information available"}]